Nebivolol Glenmark (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Glenmark, is a beta‑blocker presented as a tablet for oral use. It is used to treat hypertension and may be prescribed for certain heart‑failure patients.

GNH USA supplies Nebivolol Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑blocker that acts on the cardiovascular system to lower blood pressure and improve heart function.

- Hypertension: reduces systolic and diastolic blood pressure, helping to control essential hypertension. - Heart failure with reduced ejection fraction: improves ventricular performance and may reduce hospitalization risk. - Cardiovascular risk management: contributes to overall risk reduction in patients with elevated blood pressure and associated comorbidities.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: often related to blood pressure changes. - Fatigue or tiredness: may occur during dose titration. - Bradycardia: slower heart rate, usually asymptomatic. - Nausea or abdominal discomfort. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block: may require medical attention. - Acute bronchospasm: especially in patients with asthma or COPD. - Allergic reactions: rash, itching, or angioedema. - Hepatic dysfunction: elevated liver enzymes. - Hypotension: marked drop in blood pressure leading to syncope. - Depression or mood changes: rare but reported.

Before initiating Nebivolol, clinicians should evaluate patient history and monitor relevant parameters. - Cardiovascular assessment: verify baseline heart rate and blood pressure. - Asthma or COPD: use with caution due to potential bronchospasm. - Diabetes: monitor blood glucose as symptoms of hypoglycemia may be masked. - Renal or hepatic impairment: dose adjustment may be required. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; careful review is advised.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma levels. - Non‑selective β‑blockers combined with nebivolol: heightened cardiovascular depression.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: may enhance hypotensive effect. - Diuretics: increase risk of orthostatic hypotension. - Antidiabetic agents: may mask hypoglycemia symptoms, requiring glucose monitoring.